Robert Califf (Michael Brochstein/Sipa USA via AP Images)

Ed­i­to­r­i­al: With Califf con­firmed, FDA needs to re­turn to pri­or­i­ties lost to the pan­dem­ic and im­prove its mes­sag­ing

The pan­dem­ic is by no means over, and the FDA will sure­ly con­tin­ue to pri­or­i­tize the nec­es­sary EUAs for ad­di­tion­al ther­a­pies and tar­get­ed vac­cines as well as oth­er mea­sures to bring down the bal­loon­ing death toll.

In fact, the first big item on new­ly Sen­ate-con­firmed FDA com­mish Rob Califf’s plate will be the or­deal around Pfiz­er’s vac­cine for the youngest chil­dren.

The FDA last week rubbed egg on its own face by not on­ly call­ing for Pfiz­er to sub­mit da­ta, but sched­ul­ing an ad­comm to re­view the da­ta on this low­est-dose vac­cine, con­tem­plat­ing start­ing with two dos­es be­fore wait­ing for da­ta on a third.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.